Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cancer Risk: A systematic review and network meta-analysis
Not Applicable
- Conditions
- Hypertension, Coronary artery disease, Heart failure, Chronic kidney disease, Atrial fibrillation, High risk vascular disease, Cerebrovascular accident, Diabetes mellitus, High normal blood pressure, Pre-hypertension
- Registration Number
- JPRN-UMIN000048395
- Lead Sponsor
- Yokohama City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Systematic review or meta-analysis articles. (2) Retrospective analysis. (3) Single prospective cohort study without a control group. (4) Non-RCT. (5) The republished research literature is excluded unless the research includes new findings related to cancers listed in inclusion criteria. (6) Studies with no or insufficient safety outcomes at the time of the literature search. Two investigators independently will screen all titles, abstracts, and full texts for eligibility. Final inclusion will be decided after resolving discrepancies between the two investigators.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The odds ratio (OR) of cancer with ARNI will be calculated. Network meta-analysis will be performed to compare the incidence of cancer between ARNI and control treatment. We will use five comparison categories: placebo, ARNI, angiotensin-converting-enzyme inhibitors (ACEi), angiotensin-receptor blockers (ARBs), ACEi and ARBs.
- Secondary Outcome Measures
Name Time Method The odds ratio (OR) of cancer with ACEi, ARBs, ACEi and ARBs will be calculated. The main analysis will be compared individual drug classes with placebo, which will be used as reference.